Medinol Ltd

Medinol’s core technology is multidisciplinary as well as multidimensional. Medinol is the only company that applies its pattern formation process to a flat panel. Only after the pattern is created and automatically inspected from both sides, is the flat lattice folded and fused to create a cylindrical stent This unique two dimensional pattern formation process allows us to achieve unparalleled precision. Additionally, it allows us to conduct quality control processes on both sides of the flat panel using Automated Visual Inspection (AVI) – a technology adopted from the micro-electronics industry. The two dimensional nature of our pattern formation process also facilitates the use of two different cutout technologies – chemical etching and water jet laser cutting. The ability to choose between these alternative technologies allows us to match each stent material with the optimal technology. Additionally, these cutting technologies involve minimum heat trauma, resulting in higher metal properties. Medinol develops, manufactures, and markets EluNIR™, the first elastomeric drug eluting stent. Made from thin cobalt-chrome alloy and recognized for its unique flexibility, conformability and scaffolding, EluNIR offers new level of uniform drug elution and surface quality, and demonstrated excellent clinical outcomes and promising safety profile in two clinical studies. EluNIR features the revolutionary Flexx²™ catheter technology with a spring-tip that eliminates tip flare-out and buckling. Flexx² overcomes traditional polymer tip limitations, offering simultaneously better flexibility and better crossability, resulting in unprecedented ease-of-delivery even in tough anatomies.

Patients, Physicians, Hospitals, Health Care Providers

Yoram Richter - CEO

Eran Kaplan - CTO

Dafna Perlovitch - CFO